A Clinical Workflow for Cost-Saving High-Rate Diagnosis of Genetic Kidney Diseases

Abstract

Significance Statement To optimize the diagnosis of genetic kidney disorders in a cost-effective manner, we developed a workflow based on referral criteria for in-person evaluation at a tertiary center, whole-exome sequencing, reverse phenotyping, and multidisciplinary board analysis. This workflow reached a diagnostic rate of 67%, with 48% confirming and 19% modifying the suspected clinical diagnosis. We obtained a genetic diagnosis in 64% of children and 70% of adults. A modeled cost analysis demonstrated that early genetic testing saves 20% of costs per patient. Real cost analysis on a representative sample of 66 patients demonstrated an actual cost reduction of 41%. This workflow demonstrates feasibility, performance, and economic effect for the diagnosis of genetic kidney diseases in a real-world setting. Background Whole-exome sequencing (WES) increases the diagnostic rate of genetic kidney disorders, but accessibility, interpretation of results, and costs limit use in daily practice. Methods Univariable analysis of a historical cohort of 392 patients who underwent WES for kidney diseases showed that resistance to treatments, familial history of kidney disease, extrarenal involvement, congenital abnormalities of the kidney and urinary tract and CKD stage ≥G2, two or more cysts per kidney on ultrasound, persistent hyperechoic kidneys or nephrocalcinosis on ultrasound, and persistent metabolic abnormalities were most predictive for genetic diagnosis. We prospectively applied these criteria to select patients in a network of nephrology centers, followed by centralized genetic diagnosis by WES, reverse phenotyping, and multidisciplinary board discussion. Results We applied this multistep workflow to 476 patients with eight clinical categories (podocytopathies, collagenopathies, CKD of unknown origin, tubulopathies, ciliopathies, congenital anomalies of the kidney and urinary tract, syndromic CKD, metabolic kidney disorders), obtaining genetic diagnosis for 319 of 476 patients (67.0%) (95% in 21 patients with disease onset during the fetal period or at birth, 64% in 298 pediatric patients, and 70% in 156 adult patients). The suspected clinical diagnosis was confirmed in 48% of the 476 patients and modified in 19%. A modeled cost analysis showed that application of this workflow saved 20% of costs per patient when performed at the beginning of the diagnostic process. Real cost analysis of 66 patients randomly selected from all categories showed actual cost reduction of 41%. Conclusions A diagnostic workflow for genetic kidney diseases that includes WES is cost-saving, especially if implemented early, and is feasible in a real-world setting. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2023_04_03_JASN2022060725.mp3

Comparison of different genetic testing modalities applied in paediatric patients with steroid-resistant nephrotic syndrome

“…Early and appropriate selection of genetic testing facilitates diagnostic cost savings and also avoids unnecessary follow-up therapeutic interventions, similar to other study [ 37 – 40 ]. It is worth noting that our actual cost analysis calculates the cost at the first hospitalization.…”

Precision Medicine in Diabetic Kidney Disease: A Narrative Review Framed by Lived Experience

“…Exome sequencing has been used to improve the diagnosis of monogenetic genetic kidney diseases in the setting of CKD of unknown etiology, such as podocytopathies, collagenopathies, tubulopathies, ciliopathies, but the prevalence of these co-existing disorders in the setting of diabetes is unknown. 60,61 In contrast to monogenic disease, the translational benefits following from the genetic discoveries in the more common polygenic causes of disease, including type 1 and type 2 diabetes, have been less established. Genome-wide association studies (GWAS) in DKD, conducted in patients with both type 1 and type 2 diabetes, have revealed approximately 33 genes to be associated with disease.…”

Kidney Genetics: Continuing Discoveries and a Roadmap to the Clinic

“…1 A second study provides a compelling implementation roadmap for incorporation of monogenic CKD genomic diagnostics into the clinic. 2 At least 625 genes are known to cause monogenic kidney diseases. 3 The estimated prevalence of monogenic kidney diseases is 70%, and 10%-15% in pediatric and adult populations, respectively.…”

“…1 A second study provides a compelling implementation roadmap for incorporation of monogenic CKD genomic diagnostics into the clinic. 2…”

“…A second study in this issue describes a clinical workflow for diagnosis of monogenic kidney diseases, tests its performance, and assesses its cost-effectiveness. 2 Becherucci and her coworkers first analyzed a historical cohort of 392 patients with CKD who had exome sequencing and identified seven clinical criteria that predicted a genetic diagnosis. They then established a regional network in Italy that prospectively referred patients with suspected genetic diseases and at least one selection criterion to a central center to establish a genetic diagnosis.…”